Relay Therapeutics, Inc.

NasdaqGM:RLAY 주식 보고서

시가총액: US$1.2b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Relay Therapeutics 관리

관리 기준 확인 2/4

Relay Therapeutics' CEO는 Sanjiv Patel, Mar2017 에 임명되었습니다 의 임기는 7.42 년입니다. 총 연간 보상은 $ 19.77M, 3.4% 로 구성됩니다. 3.4% 급여 및 96.6% 보너스(회사 주식 및 옵션 포함). 는 $ 9.90M 가치에 해당하는 회사 주식의 1.02% 직접 소유합니다. 9.90M. 경영진과 이사회의 평균 재임 기간은 각각 6.3 년과 5 년입니다.

주요 정보

Sanjiv Patel

최고 경영자

US$19.8m

총 보상

CEO 급여 비율3.4%
CEO 임기7.5yrs
CEO 소유권0.8%
경영진 평균 재임 기간6.4yrs
이사회 평균 재임 기간5.1yrs

최근 관리 업데이트

Recent updates

Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations

Sep 11

Here's Why We're Not Too Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Situation

Aug 03
Here's Why We're Not Too Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Situation

Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Just Trimmed Their Revenue Forecasts By 12%

Apr 17
Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Just Trimmed Their Revenue Forecasts By 12%

Relay Therapeutics: Platform More Important Than Programs

Mar 13

Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag

Feb 13

Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)

Jan 21
Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)

We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth

Nov 14
We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth

Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?

Jun 08
Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?

Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

Feb 22
Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

Oct 23
Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

Relay set to Equal Weight at Barclays; says fairly valued ahead of catalysts

Sep 30

Relay Therapeutics: Bile Duct Cancer Approval Shot Validates Pricey Platform

Sep 18

Why did Relay Therapeutics stock drop today?

Sep 09

Estimating The Fair Value Of Relay Therapeutics, Inc. (NASDAQ:RLAY)

Jan 02
Estimating The Fair Value Of Relay Therapeutics, Inc. (NASDAQ:RLAY)

Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Reducing Their Forecasts For This Year

Aug 17
Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Reducing Their Forecasts For This Year

CEO 보상 분석

Sanjiv Patel 의 보수는 Relay Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

-US$323m

Mar 31 2024n/an/a

-US$329m

Dec 31 2023US$20mUS$674k

-US$342m

Sep 30 2023n/an/a

-US$326m

Jun 30 2023n/an/a

-US$344m

Mar 31 2023n/an/a

-US$323m

Dec 31 2022US$8mUS$642k

-US$291m

Sep 30 2022n/an/a

-US$290m

Jun 30 2022n/an/a

-US$267m

Mar 31 2022n/an/a

-US$384m

Dec 31 2021US$9mUS$603k

-US$364m

Sep 30 2021n/an/a

-US$261m

Jun 30 2021n/an/a

-US$414m

Mar 31 2021n/an/a

-US$247m

Dec 31 2020US$4mUS$585k

-US$230m

Sep 30 2020n/an/a

-US$289m

Jun 30 2020n/an/a

-US$95m

Mar 31 2020n/an/a

-US$86m

Dec 31 2019US$4mUS$585k

-US$75m

보상 대 시장: Sanjiv 의 총 보상 ($USD 19.77M )은 US 시장( $USD 3.30M ).

보상과 수익: 회사가 수익성이 없는 동안 Sanjiv 의 보상이 증가했습니다.

CEO

Sanjiv Patel (50 yo)

7.5yrs

테뉴어

US$19,770,838

보상

Dr. Sanjiv K. Patel, M.A., M.D., M.B.A., MBBS, had been an Independent Director at Prothena Corporation plc since May 18, 2021 until July 1, 2023. He serves as Independent Director of ARYA Sciences Acquisi...

리더십 팀

이름위치테뉴어보상소유권
Alexis Borisy
Co-Founder & Independent Chairman9.4yrsUS$581.14k0.14%
$ 1.7m
Sanjiv Patel
CEO, President & Director7.5yrsUS$19.77m0.84%
$ 10.2m
Mark Murcko
Co-Founder & Directorno dataUS$548.64k0.61%
$ 7.4m
Thomas Catinazzo
Chief Financial Officer6.4yrsUS$5.22m0.013%
$ 152.5k
Brian Adams
Chief Legal Officer & Secretary6.5yrsUS$4.51m0.024%
$ 291.0k
Peter Rahmer
Chief Corporate Development Officerno dataUS$6.78m0.0086%
$ 104.3k
Donald Bergstrom
President of Research & Development6.4yrsUS$8.57m0.039%
$ 468.8k
Dorothee Kern
Founderno data데이터 없음데이터 없음
David Shaw
Founderno data데이터 없음데이터 없음
Matthew Jacobson
Founderno data데이터 없음데이터 없음
Jim Watters
Chief Scientific Officerless than a year데이터 없음데이터 없음
Jeanne Gray
Chief People Officerno data데이터 없음데이터 없음

6.4yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 관리: RLAY 의 관리팀은 노련하고 경험 (평균 재직 기간 6.3 년)입니다.

이사회 구성원

이름위치테뉴어보상소유권
Alexis Borisy
Co-Founder & Independent Chairman9.4yrsUS$581.14k0.14%
$ 1.7m
Sanjiv Patel
CEO, President & Director7.5yrsUS$19.77m0.84%
$ 10.2m
Mark Murcko
Co-Founder & Director8.2yrsUS$548.64k0.61%
$ 7.4m
Douglas Ingram
Independent Director5.3yrsUS$548.64k0.015%
$ 186.5k
Linda Hill
Independent Director5.9yrsUS$551.14k0%
$ 0
George Demetri
Member of Oncology Advisory Board4.5yrs데이터 없음데이터 없음
Laura Shawver
Independent Director7.5yrsUS$551.14k0.025%
$ 298.4k
Lillian Siu
Member of Oncology Advisory Board4.5yrs데이터 없음데이터 없음
Jamilu Rubin
Independent Director4.9yrsUS$558.64k0.041%
$ 501.6k
Pamela Munster
Member of Oncology Advisory Board4.5yrs데이터 없음데이터 없음
Trever Bivona
Member of Oncology Advisory Board4.5yrs데이터 없음데이터 없음
Dejan Juric
Member of Oncology Advisory Board4.5yrs데이터 없음데이터 없음

5.1yrs

평균 재임 기간

62.5yo

평균 연령

경험이 풍부한 이사회: RLAY 의 이사회는 경험(평균 재직 기간 5 년)으로 간주됩니다.